首页|构建更加科学高效权威的药品上市后监管体系更好保障公众用药安全

构建更加科学高效权威的药品上市后监管体系更好保障公众用药安全

扫码查看
建立科学高效权威的药品上市后监管体系是保障药品质量安全的必然要求,也是推动我国从制药大国向制药强国跨越、更好满足人民群众健康需求的应有之义.本文全面总结了当前我国药品上市后监管工作进展,深刻分析了当前面临的新任务和新形势,阐述了做好药品上市后监管工作的内在逻辑,展望了未来的工作方向和任务,为构建更加科学高效权威的药品上市后监管体系提供了参考.
Building a More Scientific,Efficient,and Authoritative Post-Marketing Drug Regulatory System to Enhance Public Medication Safety
Establishing a scientific,efficient,and authoritative post-marketing drug regulatory system is an essential requirement for ensuring drug quality and safety.It is also a necessary step for China to transition from a major pharmaceutical country to a powerful one,better meeting the health needs of the population.This article summarizes the current progress in post-marketing drug regulation in China,analyzes emerging challenges and situations,expounds the inherent logic of effective post-marketing drug regulation,proposes future directions and tasks,and provides references for building a more scientific,efficient,and authoritative post-marketing drug regulatory system.

post-marketing drug regulationsafety and developmentrisk prevention and resolutiondrug regulatory capacity-building

袁林

展开 >

国家药品监督管理局

药品上市后监管 安全与发展 防范化解风险 药品监管能力建设

2024

中国食品药品监管
中国医药报社

中国食品药品监管

影响因子:0.099
ISSN:1673-5390
年,卷(期):2024.(1)
  • 14